Published in Curr Drug Targets on January 01, 2015
Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells. Sci Rep (2016) 0.78
Protein-arginine deiminase 2 suppresses proliferation of colon cancer cells through protein citrullination. Cancer Sci (2017) 0.75
Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds. Oncotarget (2016) 0.75
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
RefSeq: an update on mammalian reference sequences. Nucleic Acids Res (2013) 7.29
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet (2003) 7.04
Human PAD4 regulates histone arginine methylation levels via demethylimination. Science (2004) 5.46
PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays (2003) 5.04
let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull (2006) 4.42
Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol (2011) 3.83
NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med (2013) 3.70
Ulcerative colitis. Lancet (2012) 3.38
Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry (2006) 2.92
Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis (2004) 2.82
Structural basis for Ca(2+)-induced activation of human PAD4. Nat Struct Mol Biol (2004) 2.74
Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol (2011) 2.53
Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination. Proc Natl Acad Sci U S A (2005) 2.40
Calcium orchestrates apoptosis. Nat Cell Biol (2003) 2.27
Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol (2008) 2.27
Citrullination is an inflammation-dependent process. Ann Rheum Dis (2006) 2.25
Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis. Biochemistry (2005) 2.21
N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 2.18
Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem (1996) 2.05
Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol (2006) 2.05
Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res (2014) 1.93
A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc (2006) 1.85
Neutrophils at work. Nat Immunol (2014) 1.85
Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel (2009) 1.83
Citrullination regulates pluripotency and histone H1 binding to chromatin. Nature (2014) 1.81
Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer (2009) 1.78
The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res (2006) 1.71
Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry (2010) 1.66
Deimination of arginine residues in nucleophosmin/B23 and histones in HL-60 granulocytes. Biochem Biophys Res Commun (2002) 1.66
Histone citrullination by protein arginine deiminase: is arginine methylation a green light or a roadblock? ACS Chem Biol (2006) 1.64
Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res (2000) 1.61
Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol (2011) 1.61
Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. J Neurosci Res (2005) 1.57
The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol Cancer Res (2011) 1.56
Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Ann Rheum Dis (2011) 1.45
Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun (1998) 1.42
Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J Neurosci (2006) 1.41
Ca2+-dependent deimination-induced disassembly of intermediate filaments involves specific modification of the amino-terminal head domain. J Biol Chem (1989) 1.36
Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation. Proc Natl Acad Sci U S A (2012) 1.35
Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene (2010) 1.27
RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene (2009) 1.27
Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol (1996) 1.26
Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem Biol (2011) 1.25
Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis (2014) 1.25
Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum (2010) 1.23
Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochem Biophys Res Commun (1996) 1.23
Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. J Mol Biol (2007) 1.21
Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol Life Sci (2010) 1.21
Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis. Biochim Biophys Acta (2013) 1.20
Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. Nat Commun (2012) 1.20
The protein arginine deiminases: Structure, function, inhibition, and disease. Biopolymers (2013) 1.18
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer (2012) 1.18
Functional analysis of the profilaggrin N-terminal peptide: identification of domains that regulate nuclear and cytoplasmic distribution. J Invest Dermatol (2002) 1.15
Peptidylarginine deiminase 2 (PAD2) overexpression in transgenic mice leads to myelin loss in the central nervous system. Dis Model Mech (2008) 1.14
cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type I. Biochem J (2003) 1.12
Combined biochemical and immunochemical comparison of peptidylarginine deiminases present in various tissues. Biochim Biophys Acta (1988) 1.12
Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability. Dev Biol (2011) 1.12
Detection of deiminated proteins in rat skin: probing with a monospecific antibody after modification of citrulline residues. J Invest Dermatol (1995) 1.12
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem (2007) 1.11
Potential role for PAD2 in gene regulation in breast cancer cells. PLoS One (2012) 1.08
Neutrophil extracellular traps (NETs) - formation and implications. Acta Biochim Pol (2013) 1.07
A novel microtubule independent effect of paclitaxel: the inhibition of peptidylarginine deiminase from bovine brain. Biochim Biophys Acta (1998) 1.06
Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol (2014) 1.04
The role of the vimentin intermediate filaments in rat 3Y1 cells elucidated by immunoelectron microscopy and computer-graphic reconstruction. Biol Cell (1990) 1.03
Human peptidylarginine deiminase type II: molecular cloning, gene organization, and expression in human skin. Arch Biochem Biophys (2002) 1.02
Peptidylarginine deiminases and deimination in biology and pathology: relevance to skin homeostasis. J Dermatol Sci (2006) 1.02
Decreased deiminated keratin K1 in psoriatic hyperproliferative epidermis. J Invest Dermatol (2000) 1.02
Pluripotency: citrullination unravels stem cells. Nat Chem Biol (2014) 1.01
Deimination of 70-kD nuclear protein during epidermal apoptotic events in vitro. J Histochem Cytochem (1998) 1.01
Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. J Biol Chem (2011) 1.01
Haplotypes of PADI4 susceptible to rheumatoid arthritis are also associated with ulcerative colitis in the Japanese population. Clin Immunol (2007) 1.01
Deimination of human myelin basic protein by a peptidylarginine deiminase from bovine brain. J Neurochem (1993) 0.99
Regulation of mouse oocyte microtubule and organelle dynamics by PADI6 and the cytoplasmic lattices. Dev Biol (2010) 0.98
Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis. Dis Model Mech (2012) 0.97
Nucleophosmin blocks mitochondrial localization of p53 and apoptosis. J Biol Chem (2009) 0.97
Accumulation of citrullinated proteins by up-regulated peptidylarginine deiminase 2 in brains of scrapie-infected mice: a possible role in pathogenesis. Am J Pathol (2008) 0.97
The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (2004) 0.97
Crystallization and preliminary X-ray crystallographic analysis of human peptidylarginine deiminase V. Acta Crystallogr D Biol Crystallogr (2003) 0.96
Update on peptidylarginine deiminases and deimination in skin physiology and severe human diseases. Int J Cosmet Sci (2007) 0.95
Potential role for PADI-mediated histone citrullination in preimplantation development. BMC Dev Biol (2012) 0.95
Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity. Biochemistry (2011) 0.95
Modulation of calcium-induced cell death in human neural stem cells by the novel peptidylarginine deiminase-AIF pathway. Biochim Biophys Acta (2014) 0.94
Molecular cloning of cDNAs of mouse peptidylarginine deiminase type I, type III and type IV, and the expression pattern of type I in mouse. Eur J Biochem (1999) 0.93
Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease. J Autoimmun (2012) 0.93
Properties of peptidylarginine deiminase from the epidermis of newborn rats. J Biochem (1981) 0.93
The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One (2013) 0.91
Rapid release and unusual stability of immunodominant peptide 45-89 from citrullinated myelin basic protein. Biochemistry (1999) 0.90
The developmental expression and activity of peptidylarginine deiminase in the mouse. Neurosci Lett (1999) 0.89
Discovery of peptidylarginine deiminase-4 substrates by protein array: antagonistic citrullination and methylation of human ribosomal protein S2. Mol Biosyst (2011) 0.88
Isolation and characterization of cDNA clones encoding rat skeletal muscle peptidylarginine deiminase. J Biol Chem (1989) 0.88
Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice. J Comp Neurol (2006) 0.88
Peptidylarginine deiminase 2 suppresses inhibitory {kappa}B kinase activity in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Biol Chem (2010) 0.87
D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. ACS Med Chem Lett (2012) 0.86
Vimentin is involved in peptidylarginine deiminase 2-induced apoptosis of activated Jurkat cells. Mol Cells (2014) 0.86
Dysregulation of PAD4-mediated citrullination of nuclear GSK3β activates TGF-β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. Proc Natl Acad Sci U S A (2013) 0.85
Specificity and mode of action of the muscle-type protein-arginine deiminase. Arch Biochem Biophys (1992) 0.85
PADI4 and tumourigenesis. Cancer Cell Int (2010) 0.85
Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry (2006) 2.92
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature (2008) 2.83
Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol (2008) 2.27
Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis. Biochemistry (2005) 2.21
N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 2.18
Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem (2008) 1.93
Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res (2014) 1.93
A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc (2006) 1.85
Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel (2009) 1.83
Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry (2010) 1.66
Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest (2013) 1.64
Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol (2011) 1.61
Protein arginine methyltransferase 1: positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis. Biochemistry (2007) 1.55
Protein arginine deiminase 4: evidence for a reverse protonation mechanism. Biochemistry (2007) 1.45
In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. J Am Chem Soc (2008) 1.42
Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps. Arthritis Rheum (2011) 1.38
Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation. Proc Natl Acad Sci U S A (2012) 1.35
Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells. PLoS Genet (2011) 1.33
Kinetic mechanism of protein arginine methyltransferase 1. Biochemistry (2008) 1.32
Activation of PAD4 in NET formation. Front Immunol (2012) 1.30
Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem Biol (2011) 1.25
Activity-based protein profiling reagents for protein arginine deiminase 4 (PAD4): synthesis and in vitro evaluation of a fluorescently labeled probe. J Am Chem Soc (2006) 1.24
Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol Life Sci (2010) 1.21
The protein arginine deiminases: Structure, function, inhibition, and disease. Biopolymers (2013) 1.18
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer (2012) 1.18
A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun (Camb) (2010) 1.13
An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4). Tetrahedron Lett (2008) 1.13
Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation. Chembiochem (2010) 1.13
The protein acetyltransferase ARD1: a novel cancer drug target? Curr Cancer Drug Targets (2008) 1.13
Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability. Dev Biol (2011) 1.12
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem (2007) 1.11
Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem Res Int (2012) 1.08
Peptide borono lectins (PBLs): a new tool for glycomics and cancer diagnostics. Chembiochem (2007) 1.06
Kinase consensus sequences: a breeding ground for crosstalk. ACS Chem Biol (2011) 1.04
A selective chemical probe for coenzyme A-requiring enzymes. Angew Chem Int Ed Engl (2007) 1.04
Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine (Lond) (2012) 1.00
Chemical biology of protein arginine modifications in epigenetic regulation. Chem Rev (2015) 0.99
Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity. Biochemistry (2011) 0.95
Kinetic mechanism of protein arginine methyltransferase 6 (PRMT6). J Biol Chem (2012) 0.95
Potential role for PADI-mediated histone citrullination in preimplantation development. BMC Dev Biol (2012) 0.95
Seeing citrulline: development of a phenylglyoxal-based probe to visualize protein citrullination. J Am Chem Soc (2012) 0.93
Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorg Med Chem (2003) 0.93
Mechanistic studies on transcriptional coactivator protein arginine methyltransferase 1. Biochemistry (2011) 0.93
The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One (2013) 0.91
A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation. Chembiochem (2010) 0.91
Selective HAT inhibitors as mechanistic tools for protein acetylation. Methods Enzymol (2004) 0.91
Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors. J Med Chem (2015) 0.90
Substrate specificity, processivity, and kinetic mechanism of protein arginine methyltransferase 5. Biochemistry (2013) 0.90
The tomato brassinosteroid receptor BRI1 increases binding of systemin to tobacco plasma membranes, but is not involved in systemin signaling. Plant Mol Biol (2009) 0.89
Chemical and biological methods to detect post-translational modifications of arginine. Biopolymers (2014) 0.88
Characterization and inactivation of an agmatine deiminase from Helicobacter pylori. Bioorg Chem (2009) 0.88
Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem Biol (2011) 0.88
Probing adenylation: using a fluorescently labelled ATP probe to directly label and immunoprecipitate VopS substrates. Mol Biosyst (2012) 0.87
Inhibiting AMPylation: a novel screen to identify the first small molecule inhibitors of protein AMPylation. ACS Chem Biol (2013) 0.87
A combinatorial approach to characterize the substrate specificity of protein arginine methyltransferase 1. Mol Biosyst (2010) 0.86
D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. ACS Med Chem Lett (2012) 0.86
Design, synthesis, and kinetic characterization of protein N-terminal acetyltransferase inhibitors. ACS Chem Biol (2013) 0.86
Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4. ACS Chem Biol (2011) 0.86
Mechanistic studies of protein arginine deiminase 2: evidence for a substrate-assisted mechanism. Biochemistry (2014) 0.85
Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates. J Neurochem (2014) 0.84
Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributive fashion. Biochemistry (2014) 0.84
Automethylation of protein arginine methyltransferase 8 (PRMT8) regulates activity by impeding S-adenosylmethionine sensitivity. J Biol Chem (2013) 0.83
Targeting the arginine phosphatase YwlE with a catalytic redox-based inhibitor. ACS Chem Biol (2013) 0.82
Mechanistic studies of agmatine deiminase from multiple bacterial species. Biochemistry (2010) 0.82
Human protein N-terminal acetyltransferase hNaa50p (hNAT5/hSAN) follows ordered sequential catalytic mechanism: combined kinetic and NMR study. J Biol Chem (2012) 0.81
A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs. ACS Chem Biol (2014) 0.81
Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors. Bioorg Med Chem (2004) 0.80
A novel role for protein arginine deiminase 4 in pluripotency: the emerging role of citrullinated histone H1 in cellular programming. Bioessays (2014) 0.80
Boronic acid functionalized peptidyl synthetic lectins: combinatorial library design, peptide sequencing, and selective glycoprotein recognition. ACS Comb Sci (2011) 0.77
Using unnatural amino acid mutagenesis to probe the regulation of PRMT1. ACS Chem Biol (2014) 0.75
Methyllysine analogs: rewriting the code. Nat Chem Biol (2007) 0.75